



WORKSHOP

**HEART FAILURE WITH
PRESERVED EJECTION FRACTION:
Lessons Learned
and Directions Forward Future Therapies**

Bergamo (Italy), June 14th - 16th, 2012

Organized by

OSPEDALI RIUNITI BERGAMO
Cardiovascular Department
Fondazione per la Ricerca Ospedale Maggiore

and

MEDICAL UNIVERSITY GRAZ
Department of Cardiology &
Ludwig-Boltzmann-Institute for
Translational Heart Failure Research

and

FONDAZIONE INTERNAZIONALE MENARINI

PROGRAM

Villa Gallarati Scotti
Oreno (Italy)



FONDAZIONE
INTERNAZIONALE
MENARINI

WORKSHOP

HEART FAILURE WITH PRESERVED EJECTION FRACTION: Lessons Learned and Directions Forward Future Therapies

Bergamo (Italy), June 14th - 16th, 2012

Organized by

OSPEDALI RIUNITI BERGAMO
Cardiovascular Department
Fondazione per la Ricerca Ospedale Maggiore

and


MEDICAL UNIVERSITY GRAZ
Department of Cardiology &
Ludwig-Boltzmann-Institute for
Translational Heart Failure Research

and

FONDAZIONE INTERNAZIONALE MENARINI

PROGRAM

Villa Gallarati Scotti
Oreno (Italy)



Courtesy of the author Dr. Donatella Bemporad. Painting entitled "Refill in the Villa"

The management of chronic HF with reduced ejection fraction has significantly improved over the last 2 decades, but no real progress has been made in HFrEF. Despite the high prevalence, mortality, and cost of HFrEF, large phase III international clinical trials investigating interventions to improve HFrEF outcomes have yielded disappointing results. Therefore, treatment of HFrEF remains largely empiric, and almost no acknowledged standards exist. There is no single explanation for the negative results of past HFrEF trials. Concerns are mainly related to incomplete understanding of HFrEF pathophysiology, mechanism of action of study drug, suboptimal study design, target patient population, and suboptimal center selection for trial conduct.

The Workshop “Heart failure with preserved ejection fraction: lessons learned and directions forward future therapies” will feature up-to date presentations on pharmacological and non-pharmacological interventions to improve HFrEF outcomes.

The Workshop program format includes epidemiologic aspects, diagnostic tools, lessons learnt from the past, with particular focus on new drugs and the design of effective and efficient trials in order to improve outcomes in HFrEF.

The perspective of the Workshop devoted to HFrEF will be: a) to summarise the current state of therapies and management concepts for HFrEF; b) to discuss why recent trials may have failed and how future trials in this field should be designed; and c) analyse recent data on novel therapeutic strategies. All attendants are internationally renowned experts in their fields. A summary of the results of the workshop will be published.

Michele Senni, Antonello Gavazzi, Burkert M. Pieske



FONDAZIONE
INTERNAZIONALE
MENARINI



Under the Auspices of



Federazione Italiana di Cardiologia
Italian Federation of Cardiology

Federazione Italiana di Cardiologia



Heart Failure Association of the
European Society of Cardiology

Scientific Secretariat

Michele Senni, Antonello Gavazzi
Cardiovascular Department
Ospedali Riuniti - Bergamo (Italy)

Burkert M. Pieske
Department of Cardiology &
Ludwig-Boltzmann-Institute for
Translational Heart Failure Research
Medical University - Graz (Austria)

Organizing Secretariat

Fondazione Internazionale Menarini
Via W. Tobagi, 8 - I-20068 Peschiera Borromeo (Milan, Italy)
Phone: +39 02 55308110 - Fax: +39 02 55305739
E-mail: milan@fondazione-menarini.it
Http://www.fondazione-menarini.it

Thursday, June 14th, 2012 - Afternoon

Opening and Introduction

- 14.00 **Welcome address and Introduction**
Michele Senni, Antonello Gavazzi (Bergamo, I)
and Burkert M. Pieske (Graz, A)

Chairman: **Stefan Anker** (Berlin, D)

- 14.15 **Key Lecture I**
Daniel Levy (Boston, USA)
HFpEF: definition, risk and epidemiology

- 14.45 **Key Lecture II**
Michael Frenneaux (Aberdeen, UK)
Diagnostic criteria for HFpEF: similar or different
for Consensus and Clinical Randomized Trials?

15.15 *Coffee break*

Session I How to target therapy to specific subgroup of patients

Chairpersons: **Alan G. Fraser** (Cardiff, UK)
Michele Emdin (Pisa, I)

- 15.30 **James Fang** (Cleveland, USA)
Do we need individualized diagnostic and etiologic criteria?
Discussant: **Stefan Anker** (Berlin, D)

- 15.55 **Alan G. Fraser** (Cardiff, UK)
Can we use imaging parameters for therapeutic decisions?
Discussant: **Scott D. Solomon** (Boston, USA)

- 16.20 **Ken McDonald** (Dublin, IRL)
Can we use biomarkers for prediction of therapeutic
effectiveness?
Discussant: **Michael Fu** (Göteborg, SW)

16.45 General Discussion with Speakers and Discussants

19.00 *Welcome party*

Friday, June 15th, 2012 - Morning

Session II The large trials: did they really fail, and why?

Chairpersons: **Otto A. Smiseth** (Oslo, N)
Piotr Ponikowski (Wroklaw, PL)

- 08.00 **Andrew J.S. Coats** (Norwich, UK)
RAS Inhibition in HFpEF: concepts and misconcepts
Discussant: **Piotr Ponikowski** (Wroklaw, PL)
- 08.25 **Marco Metra** (Brescia, I)
Beta-Blockers in HFpEF: evidence from trials or meta-analysis?
Discussant: **Andrew J.S. Coats** (Norwich, UK)

- 08.50 **Scott D. Solomon** (Boston, USA)
Why the large trials have possibly failed
Discussant: **James Fang** (Cleveland, USA)
- 09.10 General Discussion with Speakers and Discussants

09.45 *Coffee break*

Friday, June 15th, 2012 - Morning

Session III Emerging therapies I: targeting the heart

Chairpersons: **Gianni Cioffi** (Trento, I)
Scott Hummel (Ann Arbor, USA)

10.45	Marco Guazzi (Milan, I) PDE5-Inhibition: from theory to RELAX trial Discussant: Selma Mohammed (Rochester, USA)
11.05	Walter J. Paulus (Amsterdam, NL) PKG-Stimulation Discussant: Attila Borbely (Debrecen, HU)
11.10	Michele Senni (Bergamo, I) Late Na channel blockers: improving relaxation and coronary microcirculation? Discussant: Giuseppe Ambrosio (Perugia, I)
11.30	Pierre V. Ennezat (Lille, F) Functional mitral regurgitation and preserved ejection fraction Discussant: Mauro Gori (Bergamo, I)
11.55	General Discussion with Speakers and Discussants
12.00	<i>Lunch</i>

Friday, June 15th, 2012 - Afternoon

Session IV Emerging Therapies II: the Periphery

Chairpersons: **Dirk L. Brutsaert** (Antwerp, B)
Michael Fu (Göteborg, SW)

15.00	Piotr Ponikowski (Wroklaw, PL) New anabolics and IV iron therapy in HFpEF Discussant: Massimo Piepoli (Piacenza, I)
15.20	William Little (Winston-Salem, USA) Optimizing vascular coupling and endothelial function Discussant: Carsten Tschöpe (Berlin, D)
15.25	Walter J. Paulus (Amsterdam, NL) Optimizing metabolic control: any effects? Discussant: Roberto Trevisan (Bergamo, I)
15.45	Scott Hummel (Ann Arbor, USA) Improving renal function and fluid homeostasis Discussant: Giuseppe Remuzzi (Bergamo, I)
15.50	General Discussion with Speakers and Discussants
16.15	
16.35	
16.40	

Friday, June 15th, 2012 - Afternoon

**Session V Emerging Therapies III:
the extracellular matrix & devices**

Chairpersons: **Antonello Gavazzi** (Bergamo, I)
Carolyn Lam (Singapore, SG)

17.00	Javier Diez (Pamplona, E) Matrix alterations in HFpEF Discussant: Ken McDonald (Dublin, IRL)
17.20	Marc Pfeffer (Boston, USA) Aldosterone receptor blockade: from theory to Aldo-DHF & Topcat Discussant: Frank Edelmann (Göttingen, D)
17.45	Otto A. Smiseth (Oslo, N) Inhomogeneities in relaxation and filling-role for resynchronization? Discussant: Alan G. Fraser (Cardiff, UK)
17.50	Gaetano De Ferrari (Pavia, I) Parasympathetic modulation Discussant: Erwan Donal (Rennes, F)
18.10	General Discussion with Speakers and Discussants
18.15	
18.35	
18.40	

Saturday, June 16th, 2012 - Morning

Session VI Acute heart failure and preserved ejection fraction

Chairpersons: **Andrea Di Lenarda** (Trieste, I)
Mihai Gheorghiade (Chicago, USA)

08.00	Gerasimos Filippatos (Athens, GR) Epidemiological and diagnostic insights: defining the target population Discussant: Fabrizio Oliva (Milan, I)
08.20	Theresa A. McDonagh (London, UK) Peculiarities in the treatment of acute HFpEF patients Discussant: Hans Peter Brunner La Rocca (Maastricht, NL)
08.25	Mihai Gheorghiade (Chicago, USA) Challenges in acute HFpEF Trials
08.45	Discussant: Aldo Maggioni (Florence, I)
08.50	General Discussion with Speakers and Discussants
09.10	
09.15	
09.35	<i>Coffee break</i>

Session VII Perspectives for the future in chronic HFpEF: ways to go

Chairpersons: **Antonello Gavazzi** (Bergamo, I)
Michael Frenneaux (Aberdeen, UK)

10.00	Carolyn Lam (Singapore, SG) Sex differences in HFpEF? Discussant: Renata De Maria (Milan, I)
10.20	Burkert M. Pieske (Graz, A) Non pharmacologic interventions: exercise training and beyond Discussant: William Little (Winston-Salem, USA)
10.25	
10.50	Dirk Van Veldhuisen (Groningen, NL) Surrogate end-points in future phase II RCT? Discussant: Gerasimos Filippatos (Athens, GR)
11.10	
11.15	Aldo Maggioni (Florence, I) Which end-point in phase III RCT? Discussant: Scott D. Solomon (Boston, USA)
11.35	
11.40	General Discussion with Speakers and Discussants

Session VIII Learning from invasive hemodynamic studies

Chairman: **Burkert M. Pieske** (Graz, A)

12.00 **Eva Prokopczuk** (Foster City, USA)

The RALLI-DHF study in details

12.15 Discussant: **William Little** (Winston-Salem, USA)

12.20 **Michele Senni** (Bergamo, I)

REFILL trial protocol

12.35 General Discussion with Speakers and Discussant

Chairman: **Daniel Levy** (Boston, USA)

Key Lecture III

Marc Pfeffer (Boston, USA)

Where will we go in HFpEF management - my personal view

13.30 **Concluding Remarks**

Michele Senni (Bergamo, I), **Antonello Gavazzi** (Bergamo, I)

and **Burkert M. Pieske** (Graz, A)

GENERAL INFORMATION

Workshop venue

The venue for the Workshop will be Villa Gallarati Scotti, Oreno (Italy).

Secretariat during the Workshop

The Secretariat will be open at the following times:

Thursday, June 14th, from 01.30 p.m. to 07.00 p.m.

Friday, June 15th, from 07.45 a.m. to 06.30 p.m.

Saturday, June 16th, from 08.00 a.m. to 01.30 p.m.

Official language

The official language of the Workshop will be English.

Technical facilities

Facilities will be available for computer presentations and overhead projections.

A business center with PC (Powerpoint for Windows) will be available for check and preview of presentations. It is essential that speakers take their presentation to the business center at least one hour before the session starts.

The center will be open at the following times:

Thursday, June 14th, from 12.00 p.m. to 07.00 p.m.

Friday, June 15th, from 07.30 a.m. to 06.30 p.m.

Saturday, June 16th, from 07.30 a.m. to 01.30 p.m.

Lunches and coffee breaks

Lunches and coffee breaks will be served in the Meeting area.

LIST OF CHAIRMEN, SPEAKERS, DISCUSSANTS AND SCIENTIFIC SECRETARIES OF THE WORKSHOP

Giuseppe AMBROSIO

University of Perugia School of Medicine
Ospedale Silvestrini
Perugia (Italy)

Stefan ANKER

Applied Cachexia Research
Department of Cardiology
Charité Medical School
Campus Virchow-Klinikum
Berlin (Germany)

Attila BORBELY

Division of Clinical Physiology
Institute of Cardiology
University of Debrecen
Debrecen (Hungary)

Hans P. BRUNNER LA ROCCA

Faculty of Health Medicine and Life Sciences
Heart Failure Clinic
University Hospital Maastricht
Maastricht (The Netherlands)

Dirk L. BRUTSAERT

University of Antwerp
Antwerp (Belgium)

Gianni CIOFFI

Servizio di Ecocardiografia
Villa Bianca Trento
Trento (Italy)

Andrew J. Stewart COATS

Norwich Research Park
Norwich (UK)

Gaetano DE FERRARI

Dipartimento Cardiotoracovascolare
Cardiologia, Laboratorio Ricerca e Sperimentazione Cardiologica (U.C.C.)
Fondazione I.R.C.C.S. Policlinico San Matteo
Pavia (Italy)

Renata DE MARIA

Dipartimento Cardiotoracovascolare “A. De Gasperis”
Istituto di Fisiologia Clinica del C.N.R.
A.O. Ospedale Niguarda Ca’ Granda
Milan (Italy)

Andrea DI LENARDA

Università Ospedali Riuniti di Trieste
Trieste (Italy)

Javier DIEZ

School of Medicine, University of Navarra
Centre of Applied Medical Research
Department of Cardiology and Cardiac Surgery - University Clinic
Pamplona (Spain)

Erwan DONAL

Service de Cardiologie CCP-CHU Pontchaillou
Rennes (France)

Frank EDELMANN

Universitätsmedizin Göttingen - Georg-August-Universität
Abt. Innere Medizin, Kardiologie und Pneumologie
Göttingen (Germany)

Michele EMDIN

Division of Cardiovascular Medicine
Fondazione G. Monasterio
CNR Regione Toscana
Pisa (Italy)

Pierre Vladimir ENNEZAT

Centre Hospitalier Régional et Universitaire de Lille
Cardiology Hospital - Intensive Care Unit
Lille Cedex (France)

James FANG

Cardiovascular Medicine
Advanced Heart Failure & Transplant Center
CMO, UH Harrington Heart & Vascular Institute
UH Case Medical Center
Cleveland, Ohio (USA)

Gerasimos FILIPPATOS

Heart Failure Unit
Department of Cardiology
Attikon Athens University Hospital
Athens (Greece)

Alan G. FRASER

Wales Heart Research Institute
Cardiff University
Cardiff (UK)

Michael FRENNEAUX

University of Aberdeen
Foresterhill, Aberdeen (UK)

Michael FU
Universitetssjukhusöverläkare
Sahlgrenska University Hospital/Östra
University of Göteborg
Göteborg (Sweden)

Antonello GAVAZZI
Dipartimento Cardiovascolare
Ospedali Riuniti di Bergamo
Bergamo (Italy)

Mihai GHEORGHIADE
Center for Cardiovascular Quality and Outcomes
Northwestern University Feinberg School of Medicine
Chicago, Illinois (USA)

Mauro GORI
USC Medicina Cardiovascolare
Ospedali Riuniti di Bergamo
Bergamo (Italy)

Marco GUAZZI
Cardiology-Cardiopulmonary Laboratory
I.R.C.S. San Donato University Hospital
San Donato Milanese, Milan (Italy)

Scott HUMMEL
Department of Internal Medicine
Division of Cardiovascular Medicine
University of Michigan Health System
Ann Arbor, Michigan (USA)

Carolyn LAM
Cardiovascular Research Institute
National University Heart Centre
Singapore (SG)

Daniel LEVY
Center for Population Studies - Framingham Heart Study
National Heart, Lung and Blood Institute Framingham
Boston, Massachusetts (USA)

William LITTLE
Section on Cardiology
Wake Forest University School of Medicine
Winston-Salem, North Carolina (USA)

Aldo MAGGIONI
ANMCO Research Centre
Florence (Italy)

Theresa A. McDONAGH
King's College Hospital - Denmark Hill
London (UK)

Ken McDONALD
Crofton Cardiac Centre
Dunloaghair, Co Dublin (Ireland)

Marco METRA
Cardiology, University and Civil Hospital
Brescia (Italy)

Selma MOHAMMED
Mayo Clinic
Rochester, Minnesota (USA)

Fabrizio OLIVA
Dipartimento Cardiotoracovascolare "A. De Gasperis"
A.O. Ospedale Niguarda Ca' Granda
Milan (Italy)

Walter J. PAULUS
Department of Physiology
Institute for Cardiovascular Research VU
VU University Medical Center Amsterdam
Amsterdam (The Netherlands)

Marc PFEFFER
Brigham and Women's Hospital
Boston, Massachusetts (USA)

Massimo PIEPOLI
U.O.C. Cardiologia - Ospedale "G. da Saliceto"
Cantone del Cristo
Piacenza (Italy)

Burkert Mathias PIESKE
Department of Cardiology
Medical University Graz
Graz (Austria)

Piotr PONIKOWSKI
Department of Heart Diseases
Medical University, Faculty of Health Sciences
Clinical Military Hospital
Wroclaw (Poland)



Ewa PROKOPCZUK
Clinical Research
Gilead Sciences
Foster City, California (USA)

Giuseppe REMUZZI
Department of Immunology and Clinical Transplantation
Ospedali Riuniti di Bergamo
and Mario Negri Institute for Pharmacological Research
Bergamo (Italy)

Michele SENNI
USC Medicina Cardiovascolare
Ospedali Riuniti di Bergamo
Bergamo (Italy)

Otto A. SMISETH
Oslo University Hospital
Oslo (Norway)

Scott David SOLOMON
Harvard Medical School
Noninvasive Cardiology
Brigham and Women's Hospital
Associate Editor, Circulation
Boston, Massachusetts (USA)



Roberto TREVISAN
USC Diabetologia
Ospedali Riuniti di Bergamo
Bergamo (Italy)

Carsten TSCHÖPE
Department of Cardiology
Charité-Campus Benjamin Franklin (CBF)
Berlin (Germany)

Dirk VAN VELDHUISEN
Department of Cardiology
University Medical Center Groningen
Groningen (Netherlands)